Analysis of the statistical value of various commercially available stool tests - A comparison of one stool sample in correlation to colonoscopy;Evaluierung der statistischen Kennwerte verschiedener kommerziell erhältlicher Stuhltests ein quervergleich aus derselben stuhlprobe in korrelation zur koloskopie

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 12, 2010, Pages 557-562

  Moslein G ^a,b   Schneider, C ^b   Theilmeier, A ^c   Erckenbrecht, H ^d   Normann, S ^e   Hoffmann, B ^f   Tilmann Schmidt, D ^g   Horstmann, O ^h   Graeven, U ⁱ   Poremba, C ^j,k  

^a Düsseldorf Gegen Darmkrebs E V   (Germany)

^b St Josef Hospital   (Germany)

^c Dr Med Arno Theilmeier   (Germany)

^d Kaiserswerther Diakonie   (Germany)

^e Dr Med Stefan Normann   (Germany)

^f Augusta Hospital   (Germany)

^g Dres Med W Schmidt und D Tilmann Schmidt   (Germany)

^h SANA KLINIKUM OFFENBACH   (Germany)

ⁱ KLINIKEN MARIA HILF GMBH   (Germany)

^j HEINRICH HEINE UNIVERSITY   (Germany)

^k Zentrum fur Histologie Zytologie und Molekulare Diagnostik   (Germany)

more..

Author keywords

Colorectal cancer; Fecal occult blood test; Screening; Sensitivity; Specifity

Indexed keywords

GUAIAC;

ADVANCED CANCER; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; FECES ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; OCCULT BLOOD; PREDICTOR VARIABLE; SCREENING; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 77949769997     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1247866     Document Type: Article

References (15)

1. Burch J A., Soares-Weiser K, St John D J. et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 2007 14 132-7
2. Collins J F., Lieberman D A., Durbin T E., Weiss D G., Veterans Affairs Cooperative Study #380 Group. Accuracy of Screening for Fecal Occult Blood on a Single Stool Sample Obtained by Digital Rectal Examination: A Comparison with Recommended Sampling Practice. Ann Intern Med 2005 142 81-5
3. Hardt P D., Toepler M, Ngoumou B, Rupp J, Kloer H U. Measurement of fecal pyruvate kinase Type M2 (Tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003 23 851-4
4. Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer 2008 99 133-5
5. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008 103 1541-9
6. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009 150 162-9
7. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996 348 1467-71
8. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005 129 422-8
9. Nakama H, Yamamoto M, Kamijo N, Li T, Wei N, Fattah A S., Zhang B. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999 46 228-31
10. Rockey D C., Auslander A, Greenberg P D. Detection of upper gastrointestinal blood with fecal occult blood tests. Am J Gastroenterol 1999 94 344-50
11. Schmiegel W, Reinacher-Schick A et al. Update S3-guideline colorectal cancer 2008. Z Gastroenterol 2008 46 799-840
12. Shastri Y M., Loitsch S, Hoepffner N et al. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol 2008 103 1496-504
13. Shastri Y M., Naumann M, Oremek G M. et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 2006 119 2651-6
14. Smith R A., Cokkinides V, Brawley O W. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009 59 27-41
15. Whitlock E P., Lin J S., Liles E, Beil T L., Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008 149 638-58